Freya Biosciences License ApS: Financial statements 2022
CVR: 41372079
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Freya Biosciences License ApS (CVR 41372079) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -48,000 and a net result of DKK -48,000 compared with DKK -37,500 the year before. Equity in the 2022 report amounted to DKK 105,000. The solvency ratio was 61%.
- Gross Profit
- DKK -48,000
- Profit/Loss
- DKK -48,000
- Equity
- DKK 105,000
- Total Assets
- DKK 172,000
Official annual report
Keep an eye on Freya Biosciences License ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Freya Biosciences License ApS has published its annual report for 2021. Revenue came to DKK 0, and the net result was DKK -37,500.
As of October 7, 2022, Peter Finsel Bisgaard has joined the board of directors of Freya Biosciences License ApS.
As of October 7, 2022, Henrijette Elsebeth Richter has joined the board of directors of Freya Biosciences License ApS.
As of October 7, 2022, Colleen Denise Acosta has joined the board of directors of Freya Biosciences License ApS.
As of October 7, 2022, Mark Smith has joined the board of directors of Freya Biosciences License ApS.
As of October 7, 2022, Nicholas Haft has joined the board of directors of Freya Biosciences License ApS.
As of October 7, 2022, Colleen Denise Acosta is registered as adm. dir. of Freya Biosciences License ApS.
As of October 7, 2022, Lars Skanvig Bramhelft has stepped down as liquidator of Freya Biosciences License ApS.
On October 7, 2022, Freya Biosciences License ApS exited liquidation.
As of September 12, 2022, Lars Skanvig Bramhelft is registered as liquidator of Freya Biosciences License ApS.
About Freya Biosciences License ApS
Freya Biosciences License ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2020. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Colleen Denise Acosta. The board consists of Peter Finsel Bisgaard (chair), Claudia Maria Colciago, Colleen Denise Acosta and David Lawrence Stern. The company's owners include Danmarks Eksport- og Investeringsfond, OMX Ventures Fund I, LLC and Sofinnova Capital IX. In 2025, the company reported a gross profit of DKK -14,000 and a net result of DKK -14,000 compared with DKK -30,358 the year before. Equity in the 2025 report amounted to DKK 357,000.
